Aurora A Antibody AF3295 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemAurora A Antibody
CompanyR&D Systems, a Bio-Techne Brand
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberAF3295
NCBI Gene AliasesPPP1R47, BTAK, STK15, AURA, AIK, STK7, STK6, ARK1
ApplicationsWestern Blot, Simple Western
Conjugate/TagUnconjugated
TargetAurora A
IsotypeIgG
FormatLyophilized from a 0.2 µm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS
ReactivityHuman
HostGoat
Quantity100 ug (also 25 ug)
NCBI Full Gene Nameaurora kinase A
ClonalityPolyclonal
ImmunogenE. coli-derived recombinant human Aurora A, Met1-Glu131, Accession # O14965
ConcentrationLYOPH
PurityImmunogen affinity purified
Brand/TrademarkR&D Systems, a Bio-Techne Brand
Antibody TypePrimary Antibodies
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution

Available conjugates: Unconjugated

Specificity: Detects human Aurora A in Western blots

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

(1) The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast CancerCancer DiscoveryAugust 1, 2020Seth A. Wander et al.8516), Akt (CST, 9272), Ras (CST, clone D2C1, 8955), Aurora A (CST, clone D3E4Q, 14475; R&D systems AF3295), Cyclin E2 (CST, 4132), ERK total (CST, 3042), pERK T202/Y204 (CST, 4370, 4376), BUBR1 (Bethyl Labs,

(2) Tamoxifen Rechallenge Decreases Metastatic Potential but Increases Cell Viability and Clonogenicity in a Tamoxifen-Mediated Cytotoxicity-Resistant Subline of Human Breast MCF7 Cancer CellsFrontiers in cell and developmental biologyJanuary 1, 2020Chang YC, Cheung CHA, Kuo YL.Massachusetts, United States, cat# 2914); anti-Aurora A (R&D system, Minneapolis, Minnesota, United States, cat# AF3295); and anti–Aurora B (Genetex, Irvine, California, United States, cat# GTX130211). The PVDF membrane

(3) Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor EfficacyMolecular cancer therapeuticsDecember 1, 2019Du J, Yan L, Torres R, Gong X, Bian H, Marugán C, Boehnke K, Baquero C, Hui YH, Chapman SC, et al.

(4) Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor GeneCancer discoveryFebruary 1, 2019Gong X, Du J, Parsons SH, Merzoug FF, Webster Y, Iversen PW, Chio LC, Van Horn RD, Lin X, Blosser W, et al.

(5) Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6BloodFebruary 25, 2010Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, Basu G, Azorsa D, Perkins LM, Braggio E, et al.

Aurora A Antibody